- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06197295
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
January 27, 2024 updated by: Hui-Hsuan Lau, MD, Mackay Memorial Hospital
Efficacy and Safety of Solifenacin Combined With Mirabegron Versus Solifenacin With Vaginal Estrogen Cream for the Treatment of Detrusor Overactivity
To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Women with detrusor overactivity who were refractory to anti-muscarinics were enrolled for prospective study.
Patients were divided into two groups: one receive combined pharmacotherapy with solifenacin and mirabegron, and the other received solifenacin and vaginal estrogen cream.
Incontinence-related symptoms distress and impact on quality of life were evaluated by short form of Urinary Distress Inventory, (UDI-6), Incontinence Impact Questionnaire (IIQ-7) and Overactive Bladder Symptom Score (OABSS).
Objective outcomes include changes from baseline in episodes of daily micturition, urgency, urinary incontinence and nocturia.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hui-Hsuan Lau, MD
- Phone Number: +886-2-25433535
- Email: huihsuan1220@gmail.com
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Mackay Memorial Hospital
-
Contact:
- Jiun Chyi Hwang, MD
- Phone Number: +886-2-2543-3535
- Email: jiun1989@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.
Exclusion Criteria:
- Postvoid urine retention before treatment
- Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension
- Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.
- Women who were on hormone replacement therapy within 3 months were also excluded from the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Solifenacin with vaginal estrogen cream
Solifenacin 5mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.
|
Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
Other Names:
|
Active Comparator: Combination pharmacotherapy
Combined solifenacin 5mg and mirabegron 25mg once per day.
|
Solifenacin 5mg and Mirabegron 25mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short form of Urinary Distress Inventory (UDI-6)
Time Frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
UDI-6 is a valid questionnaire, used particularly to investigate symptoms associated with lower urinary tract dysfunction and inquire on irritative, stress, and obstructive or discomfort complaints.
UDI-6 consists of six items: frequent urination; leakage related to feeling of urgency; leakage related to activity, coughing, or sneezing; small amounts of leakage (drops); difficulty emptying the bladder; and pain or discomfort in the lower abdominal or genital area.
The total score ranges from 0 to 18 , with a higher score indicating more severe of incontinence.
|
Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Short form of Incontinence Impact Questionnaire (IIQ-7)
Time Frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
The IIQ-7 assess the impact of urinary incontinence on QoL. 7 items assess influence of urinary incontinence on physical activity, travel, social/relationships & emotional health.
Each item is scored between 0 (activities not affected at all) to 3 (activities greatly affected).
The total score ranges from 0 to 21, with a higher score indicating more severe of incontinence.
|
Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Overactive Bladder Symptom Score (OABSS)
Time Frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
The total OABSS is the sum of four symptom scores: daytime frequency (score 0-2), nighttime frequency (score 0-3), urgency (score 0-5), and urgency incontinence (score 0-5).
The total score ranges from 0 to 15, with a higher score indicating more severe of OAB symptoms.
|
Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Episodes of daily micturition
Time Frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Patients report daily lower urinary tract symptoms episodes
|
Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Episodes of daily urgency
Time Frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Patients report daily lower urinary tract symptoms episodes
|
Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Episodes of daily incontinence
Time Frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Patients report daily lower urinary tract symptoms episodes
|
Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Episodes of daily nocturia
Time Frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Patients report daily lower urinary tract symptoms episodes
|
Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hui-Hsuan Lau, MD, Mackay Memorial Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep;202(3):558-563. doi: 10.1097/JU.0000000000000309. Epub 2019 Aug 8.
- Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourol Urodyn. 2019 Feb;38(2):779-792. doi: 10.1002/nau.23919. Epub 2019 Jan 15.
- Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004 Oct;83(10):892-7. doi: 10.1111/j.0001-6349.2004.00581.x.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 16, 2022
Primary Completion (Estimated)
June 15, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
December 26, 2023
First Submitted That Met QC Criteria
December 26, 2023
First Posted (Actual)
January 9, 2024
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 27, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder, Overactive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Solifenacin Succinate
Other Study ID Numbers
- 22MMHIS039e-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder, Overactive
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on Solifenacin with vaginal estrogen cream
-
The University of Texas Medical Branch, GalvestonTerminatedPelvic Floor DisordersUnited States
-
Pamela MoalliEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingPelvic Organ ProlapseUnited States
-
Meir Medical CenterCompletedVulvovaginal Atrophy | Dyspareunia Among Puerperal WomenIsrael
-
TriHealth Inc.CompletedPelvic Organ Prolapse | Vaginal AtrophyUnited States
-
The University of Texas Health Science Center,...TerminatedVaginosis, Bacterial | Vaginal Discharge | VaginosisUnited States
-
Medstar Health Research InstitutePfizerTerminatedMicroscopic HematuriaUnited States
-
University of LouisvilleCompletedMenopause | Atrophic Vaginitis | Recurrent Urinary Tract InfectionsUnited States
-
Peking Union Medical College HospitalUnknown
-
Texas Tech University Health Sciences CenterCompleted
-
The Cleveland ClinicFoundation for Female Health AwarenessCompletedMenopause | Atrophic VaginitisUnited States